---
title: Testicular Sperm Retrieval Rate After Varicocele Ligation in Men With Non Obstructive Azoospermia
nct_id: NCT07008495
overall_status: RECRUITING
phase: NA
sponsor: South Valley University
study_type: INTERVENTIONAL
primary_condition: Non-obstructive Azoospermia
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07008495.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07008495"
ct_last_update_post_date: 2025-06-13
last_seen_at: "2026-05-12T06:26:46.713Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Testicular Sperm Retrieval Rate After Varicocele Ligation in Men With Non Obstructive Azoospermia

**Official Title:** Testicular Sperm Retrieval Rate After Varicocele Ligation in Men With Non Obstructive Azoospermia.

**NCT ID:** [NCT07008495](https://clinicaltrials.gov/study/NCT07008495)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** South Valley University
- **Conditions:** Non-obstructive Azoospermia
- **Start Date:** 2024-09-01
- **Completion Date:** 2025-08-31
- **CT.gov Last Update:** 2025-06-13

## Brief Summary

A varicocele is an abnormal dilatation and tortuosity of the veins of the spermatic cord. Although varicoceles are common in the general population and are frequently found on routine physical examinations, they represent the most common correctable cause of male factor infertility.

Male factor infertility affects up to half of all couples struggling to conceive, and 10-20% of men evaluated for infertility are found to be azoospermic.

## Detailed Description

Generally, azoospermia is classified as obstructive azoospermia (OA) or non-obstructive azoospermia (NOA). While OA is obviously caused by obstruction, NOA has many possible causes and is more difficult to manage.

Non-obstructive azoospermia (NOA) is most often a result of primary testicular dysfunction, Varicoceles are found in 20% of the general male population, in up to 40% of men with infertility, and specifically 4.3-13.3% of men with NOA.

The role of varicoceles in NOA has not been fully elucidated. The current best practice statement on the evaluation of azoospermic males from the AUA acknowledges that impaired spermatogenesis associated with varicoceles may be reversible but does not give a clear recommendation for management.

The primary advantage of varicocelectomy in cases of NOA is the possibility of getting motile sperms in the ejaculate. Other benefit of varicocele repairs in azoospermic men is that there are increased success rates of assisted reproductive techniques (ART) such as intracytoplasmic sperm injection (ICSI) or testicular sperm extraction (TESE).

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 60 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Men with non obstructive azoospermia.
* Clinically palpable varicocele ( unilateral or bilateral ).

Exclusion Criteria:

* Known cases of obstructive azoospermia.
* Non palpable varicocele.
* Uncorrectable female causes of infertility.
* genetic abnormalities like klinefelter syndrome.
```

## Arms

- **Group of varicocele ligation** (ACTIVE_COMPARATOR) — About 25 male patients will undergo varicocele ligation then microTESE.
- **Group of TESE** (ACTIVE_COMPARATOR) — About 25 male patients will undergo microTESE without varicocele ligation.

## Interventions

- **varicocelectomy** (PROCEDURE) — to detect testicular sperm retrieval rate after varicocelectomy in men with non obstructive azoospermia.

## Primary Outcomes

- **Sperm retrieval rate** _(time frame: Two Weeks)_ — Evaluation of Sperm retrieval rate after varicocelectomy in men with non obstructive azoospermia

## Secondary Outcomes

- **fertility rate** _(time frame: 3 months from the operation)_

## Locations (1)

- South Valley University Hospital, Qina, South Valley, Egypt — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.south valley university hospital|qina|south valley|egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07008495.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07008495*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*